论文部分内容阅读
目的探讨胸腺肽α1对老年B细胞性慢性淋巴细胞白血病(B cell chronic lymphatic leukemia,B-CLL)患者来源的细胞因子诱导的杀伤细胞(cytokine induced killer cells,CIK)扩增及杀瘤活性的影响。方法以胸腺肽α1作为免疫增强方案,1.6mg/d皮下注射,14d为1周期。采集4例B-CLL老年患者外周血单核细胞,每周1次,分别在应用胸腺肽α1前和应用1周期后各采集3次,在体外经干扰素-γ(IFN-γ)、白介素-2(IL-2)及抗CD3单克隆抗体诱导成CIK细胞,检测其扩增数量、效应细胞扩增倍数、淋巴细胞亚群比例及体外杀瘤活性。结果 4例在胸腺肽α1治疗前后各做12次CIK细胞培养,培养时间(13.8±1.4)d,细胞存活率95.46%±3.12%。培养后CD3+、CD8+、CD3+CD8+及CD3+CD56+T细胞比例均显著升高(P<0.05),CD3+CD4+T细胞比例无显著变化(P>0.05)。胸腺肽α1治疗后,CIK细胞在扩增数量、效应细胞扩增倍数、比例及体外杀瘤活性明显高于治疗前(P<0.05)。结论胸腺肽α1能够增强老年B-CLL患者CIK细胞体外扩增活性。
Objective To investigate the effect of thymosin α1 on cytokine induced killer cell (CIK) expansion and tumorigenicity in elderly patients with B-cell chronic lymphatic leukemia (B-CLL). Methods Thymosin α1 was used as an immunostimulation regimen and subcutaneously injected at 1.6 mg / d for 14 days. Peripheral blood mononuclear cells (PBMCs) from 4 elderly patients with B-CLL were collected once a week for 3 times before administration of thymosin α1 and 1 week after application. IFN-γ, IL- 2 (IL-2) and anti-CD3 monoclonal antibodies were induced into CIK cells to detect the number of expansion, multiples of effector cells, lymphocyte subsets and in vitro cytotoxic activity. Results Four cases of CIK cells were cultured 12 times before and after thymosin α1 treatment. The incubation time (13.8 ± 1.4) days and cell survival rate were 95.46% ± 3.12%. The proportion of CD3 +, CD8 +, CD3 + CD8 + and CD3 + CD56 + T cells in culture increased significantly (P <0.05), while the proportion of CD3 + CD4 + T cells did not change significantly (P> 0.05). Thymosin α1 treatment, CIK cells in the number of expansion, multiples of effector cells, the ratio and in vitro cytotoxic activity was significantly higher than before treatment (P <0.05). Conclusion Thymosin α1 can enhance the in vitro expansion activity of CIK cells in elderly B-CLL patients.